Sumitomo Pharma America, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00571428
A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects
Phase 1
Completed
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2011-09-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00549666
- Locations
- 🇺🇸
Covance Global Clinical Pharmacology, Inc., San Diego, California, United States
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 489
- Registration Number
- NCT00549718
- Locations
- 🇺🇸
Clinical Innovations, Inc., Costa Mesa, California, United States
🇺🇸Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3, Garden Grove, California, United States
🇺🇸Center for Behavioral Health, LLC, Rockville, Maryland, United States
A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
Phase 3
Completed
- Conditions
- Major Depressive DisorderInsomnia
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 678
- Registration Number
- NCT00435279
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseBronchitisEmphysema
- Interventions
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 235
- Registration Number
- NCT00424528
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 550
- Registration Number
- NCT00409539
- Locations
- 🇪🇪
Tartu University Clinic, Tartu, Estonia
🇵🇱Medical University of Selesia, Katowice, Poland
🇵🇱UI.G. Narutowicza 28, Lodz, Poland
A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 388
- Registration Number
- NCT00386334
- Locations
- 🇺🇸
Anderson Pharmaceutical Research, Anderson, South Carolina, United States
Study of an Evening Dose of Eszopiclone on Next Day Driving Ability & Psychomotor/Memory Function in Healthy Volunteers
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00368160
- Locations
- 🇬🇧
HPRU Medical Research Centre, Guildford, Surrey, United Kingdom
Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT00367965
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
Phase 3
Completed
- Conditions
- InsomniaDepressive Disorder, Major
- Interventions
- Other: Placebo
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 545
- Registration Number
- NCT00368030
© Copyright 2025. All Rights Reserved by MedPath